Top-Rated StocksTop-RatedNASDAQ:RGEN Repligen (RGEN) Stock Forecast, Price & News $160.21 -0.79 (-0.49%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$157.17▼$162.5850-Day Range$157.53▼$176.5152-Week Range$134.64▼$225.62Volume353,797 shsAverage Volume559,413 shsMarket Capitalization$8.93 billionP/E Ratio66.20Dividend YieldN/APrice Target$199.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Repligen MarketRank™ ForecastAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside24.2% Upside$199.00 Price TargetShort InterestBearish10.63% of Float Sold ShortDividend StrengthN/ASustainability-1.33Upright™ Environmental ScoreNews Sentiment0.93Based on 13 Articles This WeekInsider TradingSelling Shares$145,673 Sold Last QuarterProj. Earnings Growth36.00%From $1.75 to $2.38 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.44 out of 5 starsMedical Sector220th out of 975 stocksBiological Products, Except Diagnostic Industry30th out of 162 stocks 2.4 Analyst's Opinion Consensus RatingRepligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $199.00, Repligen has a forecasted upside of 24.2% from its current price of $160.21.Amount of Analyst CoverageRepligen has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.63% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Repligen has recently increased by 1.29%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRepligen does not currently pay a dividend.Dividend GrowthRepligen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRepligen has received a 68.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Spin filters", "Protein gels", and "Chromatography columns" products. See details.Environmental SustainabilityThe Environmental Impact score for Repligen is -1.33. Previous Next 3.8 News and Social Media Coverage News SentimentRepligen has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Repligen this week, compared to 4 articles on an average week.Search Interest6 people have searched for RGEN on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Repligen to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Repligen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $145,673.00 in company stock.Percentage Held by InsidersOnly 1.10% of the stock of Repligen is held by insiders.Percentage Held by Institutions97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Repligen are expected to grow by 36.00% in the coming year, from $1.75 to $2.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repligen is 66.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Repligen is 66.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 123.06.Price to Earnings Growth RatioRepligen has a PEG Ratio of 3.79. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRepligen has a P/B Ratio of 4.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Repligen (NASDAQ:RGEN) StockRepligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.Read More RGEN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGEN Stock News HeadlinesSeptember 27, 2023 | finance.yahoo.comRepligen (RGEN) to Acquire Fluid Management Company MetenovaSeptember 26, 2023 | markets.businessinsider.comLife Sciences Player Repligen's Strategic European Acquisition - What It Means for InvestorsSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 26, 2023 | finance.yahoo.comWaltham's Repligen to acquire Swedish firmSeptember 26, 2023 | finance.yahoo.comRepligen Announces Agreement to Acquire Fluid Management Innovator MetenovaSeptember 26, 2023 | finance.yahoo.comRepligen Announces Agreement to Acquire Fluid Management Innovator MetenovaSeptember 25, 2023 | americanbankingnews.comRepligen Co. (NASDAQ:RGEN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 18, 2023 | finance.yahoo.comIs There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 21% Undervaluation?September 28, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 12, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Streamline Health Solutions (STRM), Repligen (RGEN)September 12, 2023 | finance.yahoo.comRepligen Appoints Jason K. Garland as Chief Financial OfficerSeptember 6, 2023 | msn.comRBC Capital Reiterates Repligen (RGEN) Outperform RecommendationSeptember 6, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About RepligenSeptember 6, 2023 | finance.yahoo.comReasons For the Decline of Repligen Corporation (RGEN)September 1, 2023 | finance.yahoo.comDrug Developer Stocks Are Risky. Why a Picks-and-Shovels Approach Makes Sense.September 1, 2023 | finance.yahoo.comRepligen Corporation to Present at Wells Fargo Healthcare ConferenceAugust 30, 2023 | markets.businessinsider.comRepligen (RGEN) Receives a Buy from RBC CapitalAugust 21, 2023 | finance.yahoo.comWhat Makes Repligen Corporation (RGEN) a Quality Investment?August 17, 2023 | finance.yahoo.comSartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process IntensificationAugust 10, 2023 | finance.yahoo.comMultiple Headwinds Impacted Repligen Corp. (RGEN)’s Performance in Q2August 9, 2023 | finance.yahoo.comNews Flash: 14 Analysts Think Repligen Corporation (NASDAQ:RGEN) Earnings Are Under ThreatAugust 3, 2023 | msn.comStephens & Co. Maintains Repligen (RGEN) Overweight RecommendationAugust 3, 2023 | finance.yahoo.comRepligen (RGEN) Beats on Q2 Earnings, Lowers '23 GuidanceAugust 2, 2023 | finance.yahoo.comRepligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial GuidanceAugust 2, 2023 | finance.yahoo.comRepligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial GuidanceAugust 2, 2023 | finance.yahoo.comRepligen (RGEN) Q2 Earnings Surpass EstimatesJuly 31, 2023 | finance.yahoo.comWhat Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?See More Headlines Receive RGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. Email Address RGEN Company Calendar Last Earnings8/02/2023Today9/28/2023Next Earnings (Estimated)11/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:RGEN CUSIP75991610 CIK730272 Webwww.repligen.com Phone(781) 250-0111Fax781-250-0115Employees2,025Year Founded1981Price Target and Rating Average Stock Price Forecast$199.00 High Stock Price Forecast$240.00 Low Stock Price Forecast$165.00 Forecasted Upside/Downside+24.1%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$2.42 Trailing P/E Ratio66.24 Forward P/E Ratio91.61 P/E Growth3.79Net Income$185.96 million Net Margins18.92% Pretax Margin22.17% Return on Equity7.83% Return on Assets5.95% Debt Debt-to-Equity RatioN/A Current Ratio2.67 Quick Ratio2.03 Sales & Book Value Annual Sales$801.54 million Price / Sales11.15 Cash Flow$4.39 per share Price / Cash Flow36.50 Book Value$34.41 per share Price / Book4.66Miscellaneous Outstanding Shares55,760,000Free Float55,143,000Market Cap$8.94 billion OptionableOptionable Beta1.00 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Anthony J. Hunt (Age 59)Pres, CEO & Director Comp: $1.59MMr. Jon K. Snodgres (Age 57)Chief Financial Officer Comp: $838.89kMr. James R. Bylund (Age 59)Chief Operating Officer Comp: $820.26kMs. Christine Gebski (Age 54)Sr. VP of Filtration & Chromatography Comp: $625.76kMr. Ralf Kuriyel (Age 64)Sr. VP of R&D Comp: $661.75kMr. Keith Lee RobinsonChief Information OfficerMs. Sondra S. NewmanGlobal Head of Investor RelationsMs. Kimberly A. CornwellGen. CounselDr. Jaime M. Humara Ph.D.Sr. VP of MarketingMr. Neil WhitfieldVP of SalesMore ExecutivesKey CompetitorsExelixisNASDAQ:EXELNeurocrine BiosciencesNASDAQ:NBIXHalozyme TherapeuticsNASDAQ:HALOQiagenNYSE:QGENBio-TechneNASDAQ:TECHView All CompetitorsInsiders & InstitutionsPortside Wealth Group LLCBought 28,333 shares on 9/1/2023Ownership: 0.051%Karen A DawesSold 850 sharesTotal: $145,673.00 ($171.38/share)Wolverine Trading LLCBought 1,800 shares on 8/23/2023Ownership: 0.000%Comerica BankBought 8,530 shares on 8/22/2023Ownership: 0.015%California State Teachers Retirement SystemSold 2,783 shares on 8/21/2023Ownership: 0.154%View All Insider TransactionsView All Institutional Transactions RGEN Stock - Frequently Asked Questions Should I buy or sell Repligen stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RGEN shares. View RGEN analyst ratings or view top-rated stocks. What is Repligen's stock price forecast for 2023? 9 brokers have issued 12-month price objectives for Repligen's shares. Their RGEN share price forecasts range from $165.00 to $240.00. On average, they expect the company's stock price to reach $199.00 in the next twelve months. This suggests a possible upside of 24.1% from the stock's current price. View analysts price targets for RGEN or view top-rated stocks among Wall Street analysts. How have RGEN shares performed in 2023? Repligen's stock was trading at $169.31 at the beginning of the year. Since then, RGEN stock has decreased by 5.3% and is now trading at $160.31. View the best growth stocks for 2023 here. When is Repligen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. View our RGEN earnings forecast. How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) announced its earnings results on Wednesday, August, 2nd. The biotechnology company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.04. The biotechnology company earned $159.20 million during the quarter, compared to analyst estimates of $165.93 million. Repligen had a net margin of 18.92% and a trailing twelve-month return on equity of 7.83%. Repligen's revenue for the quarter was down 23.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.91 EPS. What ETFs hold Repligen's stock? ETFs with the largest weight of Repligen (NASDAQ:RGEN) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Invesco Biotechnology & Genome ETF (PBE), BlackRock Future Innovators ETF (BFTR), Fidelity Disruptive Medicine ETF (FMED), VanEck Biotech ETF (BBH), Nuveen ESG Mid-Cap Growth ETF (NUMG), BNY Mellon Innovators ETF (BKIV) and Invesco ESG NASDAQ Next Gen 100 ETF (QQJG). What guidance has Repligen issued on next quarter's earnings? Repligen issued an update on its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided EPS guidance of $1.72-$1.80 for the period, compared to the consensus earnings per share estimate of $2.29. The company issued revenue guidance of $635.00 million-$665.00 million, compared to the consensus revenue estimate of $721.07 million. What is Tony J. Hunt's approval rating as Repligen's CEO? 13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW). What is Repligen's stock symbol? Repligen trades on the NASDAQ under the ticker symbol "RGEN." Who are Repligen's major shareholders? Repligen's stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (2.96%), Sands Capital Management LLC (2.86%), Brown Capital Management LLC (2.59%), Artisan Partners Limited Partnership (2.51%), Bank of New York Mellon Corp (1.90%) and Impax Asset Management Group plc (1.82%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr. View institutional ownership trends. How do I buy shares of Repligen? Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Repligen's stock price today? One share of RGEN stock can currently be purchased for approximately $160.31. How much money does Repligen make? Repligen (NASDAQ:RGEN) has a market capitalization of $8.94 billion and generates $801.54 million in revenue each year. The biotechnology company earns $185.96 million in net income (profit) each year or $2.42 on an earnings per share basis. How many employees does Repligen have? The company employs 2,025 workers across the globe. Does Repligen have any subsidiaries? The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.Read More How can I contact Repligen? Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The official website for the company is www.repligen.com. The biotechnology company can be reached via phone at (781) 250-0111, via email at investors@repligen.com, or via fax at 781-250-0115. This page (NASDAQ:RGEN) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.